Effect of carvedilol on premature ventricular complexes originating from the ventricular outflow tract
10.1186/s42444-020-00015-7
- Author:
Jongmin HWANG
1
;
Kyoungmin LEE
;
Seongwook HAN
;
Han‑Joon BAE
;
Sang Woong CHOI
;
Cheol Hyun LEE
;
In‑Cheol KIM
;
Yun‑Kyeong CHO
;
Hyoung‑Seob PARK
;
Hyuck‑Jun YOON
;
Hyungseop KIM
;
Chang‑Wook NAM
;
Seung‑Ho HUR
Author Information
1. Cardiovascular Center, Keimyung University Dongsan Hospital, 1035 Dalgubeol‑daero, Dalseo‑gu, Daegu 42601, Republic of Korea
- Publication Type:RESEARCH
- From:International Journal of Arrhythmia
2020;21(2):e7-
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Background:Carvedilol is one of the most effective beta-blockers in reducing ventricular tachyarrhythmias and mortality in patients with heart failure. One of the possible antiarrhythmic mechanisms of carvedilol is the suppression of store overload-induced Ca2+ release, especially for the triggered activity.
Objectives:Premature ventricular complex (PVC) originating from the ventricular outflow tract (OT) is the most common form of idiopathic PVC, and its main mechanism is related to triggered activity. We evaluate the efficacy of carvedilol to suppress the OT PVC.
Methods:The electronic medical records at our hospital were screened to identify OT PVC patients treated with carvedilol. Clinical, electrocardiographic, and Holter monitoring studies were reviewed.
Results:A total of 25 patients who underwent Holter monitoring before and after carvedilol administration were found and enrolled. The mean age of the patients was 54.9 ± 13.9 years, and the mean dose of carvedilol was 18.2 ± 10.2 mg (sustained release formulation, 8/16/32 mg). The 24-h burden of PVC in 18 (72%) of 25 patients was significantly reduced from 12.2 ± 9.7% to 4.4 ± 6.7% (P = 0.006). In seven patients, the burden of PVC was changed from 7.1 ± 6.1% to 9.8 ± 8.4% (P = 0.061). There was no difference in age, carvedilol dose, duration of treatment, ventricular function, and left atrial size between responding and non-responding groups.
Conclusion:In this retrospective pilot study, treatment with carvedilol showed PVC suppression in 72% of patients. Now, we are conducting a prospective, randomized, multicenter study to evaluate the effect of carvedilol on OT PVC (Clinical trial registration: FOREVER trial, Clinical-Trials.gov: NCT03587558).
